Geneva:
AstraZeneca’s Chief Executive mentioned on Tuesday that the benefits of a study displaying its COVID-19 vaccine had tiny impact against mild illness had been regarding but stressed that it ought to work against extreme types.
“It is of course a concern,” Pascal Soriot mentioned of the study at a World Health Organization meeting.
“Having said that the patients in the study were patients with mild disease and we believe the vaccine should still protect against severe disease.”
AstraZeneca is a big supplier to a WHO-backed vaccine-sharing scheme referred to as COVAX.
()